PHARMACOKINETICS AND TISSUE PENETRATION OF RUFLOXACIN, A LONG-ACTING QUINOLONE ANTIMICROBIAL AGENT

被引:31
|
作者
WISE, R [1 ]
JOHNSON, J [1 ]
OSULLIVAN, N [1 ]
ANDREWS, JM [1 ]
IMBIMBO, BP [1 ]
机构
[1] MEDIOLANUM FARMACEUT,MILAN,ITALY
关键词
D O I
10.1093/jac/28.6.905
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The pharmacokinetics of rufloxacin after a single 400 mg oral dose were studied in eight volunteers, measuring plasma, inflammatory fluid and urine concentrations. Mean peak plasma concentrations of 4-4 mgL were achieved at a mean time of 1-9 h after administration. The mean plasma elimination half-life was 28-2 h. Mean peak levels in inflammatory fluid reached 3-2 mgL after 3-5 h, and 30-7 of the dose was eliminated in urine by 96 h. The apparent mean volume of distribution of rufloxacin, at steady state, was 109-5 L. The mean percentage penetration of rufloxacin into the inflammatory exudate, as measured by ratios of AUQ JO h was 90. © 1991 by The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:905 / 909
页数:5
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF 2 NEW LONG-ACTING ESTROGENS IN THE RAT
    CLAUSSEN, C
    STEINER, G
    RACHE, K
    NAUMANN, A
    CHEMNITIUS, KH
    PHARMAZIE, 1979, 34 (5-6): : 326 - 326
  • [22] COMPARATIVE PHARMACODYNAMICS AND PHARMACOKINETICS OF CONVENTIONAL AND LONG-ACTING PROPRANOLOL
    GARG, DC
    JALLAD, NS
    MISHRIKI, A
    CHALAVARYA, G
    KRAML, M
    FENCIK, M
    WEIDLER, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (05): : 390 - 396
  • [23] PHARMACOKINETICS OF LONG-ACTING PROPRANOLOL - IMPLICATIONS FOR THERAPEUTIC USE
    NACE, GS
    WOOD, AJJ
    CLINICAL PHARMACOKINETICS, 1987, 13 (01) : 51 - 64
  • [24] The pharmacokinetics of a long-acting formulation of oxytetracycline in sheep and goats
    Escudero, E
    Carceles, CM
    Ponferrada, C
    Baggot, JD
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) : 75 - 77
  • [25] Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
    Heres, Stephan
    Kraemer, Susanne
    Bergstrom, Richard F.
    Detke, Holland C.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 299 - 312
  • [26] 2 COMPARTMENT PHARMACOKINETICS OF LONG-ACTING ORAL THEOPHYLLINE
    LAWYER, C
    GERBER, N
    MORRIS, J
    ROGERS, R
    BARDANA, E
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1979, 119 (04): : 73 - 73
  • [27] COMPARATIVE PHARMACODYNAMICS AND PHARMACOKINETICS OF CONVENTIONAL AND LONG-ACTING PROPRANOLOL
    TAKAHASHI, H
    OGATA, H
    KANNO, S
    KASHIWADA, K
    OHIRA, M
    SOMEYA, K
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (11) : S119 - S119
  • [28] Population pharmacokinetics and dosing of long-acting injectable antipsychotics
    Kim, David D.
    Barr, Alasdair M.
    Rafizadeh, Reza
    Procyshyn, Ric M.
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2021, 46 (05): : E516 - E517
  • [29] Long-acting anticoagulant rodenticide poisoning - Bromadiolone pharmacokinetics
    Lo, M. H.
    Yuen, L. Y. P.
    Lam, Y. H.
    Lai, C. K.
    Mak, T. W. L.
    Chan, A. Y. W.
    CLINICAL TOXICOLOGY, 2006, 44 (05): : 661 - 661
  • [30] Pharmacokinetics assessment of moxidectin long-acting formulation in cattle
    Dupuy, J.
    Sutra, J. F.
    Alvinerie, M.
    VETERINARY PARASITOLOGY, 2007, 147 (3-4) : 252 - 257